383 people, a headset and 30 minutes a night: a new PTSD trial result
What happened
Post-traumatic stress disorder is hard to treat and hard to live with. The best treatments we have are talking therapies that work through the trauma directly. They work well for many people. They also require a trained therapist, a waiting list, and the emotional stamina to keep going. So results from a new trial are worth a careful look. Researchers tested a headset that sends a very low-level electrical current through the skin just behind each ear. This stimulates the vestibular nerve, the nerve that normally tells your brain about balance and head position. That nerve connects onward to the brainstem and hypothalamus, parts of the brain involved in sleep, body clock and the stress response. The device does not stimulate the brain directly. The trial recruited 383 adults with PTSD, aged 22 to 74, across the United States. It ran remotely, in people's own homes, for 12 weeks. Participants wore the headset for 30 minutes a day, about an hour before bed. Half got a working device. Half got a dummy, or 'sham', device that looked and felt the same. Neither the participants nor the researchers knew who had which. The results were published in Nature Mental Health on 23 September 2026, by Peter Colvonen of the University of California San Diego and colleagues, working with the Belfast-based company Neurovalens, which makes the device.
Why this matters
Two things make this trial stand out. The first is the comparison. Many wellbeing gadgets are sold on the back of studies where everyone knew they were getting the real thing. That is a recipe for a placebo effect. This trial used a convincing dummy device and kept everyone in the dark. That is the harder, more honest test, and far fewer products pass it. The second is where it happened. This was done at home, by post, without clinic visits. If a treatment only works inside a research centre, it helps very few people. If it works in a living room in an ordinary town, it can reach many more. For context, PTSD affects roughly 4 in 100 people in England at some point, and a good deal more among veterans, emergency workers and survivors of violence. NHS talking therapy waits for trauma-focused treatment can run into many months.
What the evidence actually says
Here is what the trial found, and what it did not. Symptoms were measured using the PTSD Checklist, a standard questionnaire. Scores fell by 23.5 points in the group using the real headset and by 12.1 points in the sham group. That is a difference of 11.4 points in favour of the device. Notice that the dummy group improved too, and by a lot. That is normal in mental health trials and it is exactly why the sham group exists. The honest result is the gap between the two, not the headline number. People using the real device also reported better sleep, better quality of life and less generalised anxiety. Side effects were mild. About 9% reported mild dizziness, and there was no difference between the real and dummy groups on adverse events. The limits are real and the authors state them. Twelve weeks is a short window, so nobody knows whether the benefit lasts. The result needs to be repeated by other teams. The trial was largely civilian, so it needs testing in military and veteran groups. And the manufacturer was involved in the research, which is common but always worth knowing. Most importantly, the authors do not present this as a replacement for trauma-focused therapy. They present it as something that might sit alongside it. In regulatory terms, the US Food and Drug Administration authorised the device for home use in PTSD in May 2026. That is a US decision. It does not mean the device is available or funded on the NHS.
Practical advice
If you or someone close to you lives with PTSD, this news does not change what to do next week. It does add to what may be possible later. Start with your GP. Trauma-focused CBT and EMDR are the treatments NICE recommends, and they have the strongest evidence behind them. In England you can also refer yourself to NHS Talking Therapies without going through a GP. If you are struggling now, contact your GP, NHS 111, or Samaritans on 116 123, free, at any hour. If someone is in immediate danger, call 999. Be cautious about buying nerve-stimulation devices online. A device authorised in the United States is not automatically approved in the UK, and many cheaper lookalike products have no trial evidence at all. In the UK, check for a UKCA or CE mark and ask your GP before spending money. Do not stop prescribed medicines or leave a therapy programme because of a news story. Improvement in PTSD is usually gradual and unsteady, and stopping early is a common reason treatment fails. If you are a veteran in the UK, Op COURAGE is the NHS mental health service designed specifically for veterans and their families.
What to know
In a 12-week trial of 383 adults with PTSD, a home-use vestibular nerve stimulation headset reduced symptom scores by 23.5 points compared with 12.1 points for a dummy device. Sleep, anxiety and quality of life also improved, and side effects were mild. It is a well-designed trial with a proper sham comparison, which is more than most wellbeing devices can claim. It is also short, needs replicating, was funded with manufacturer involvement, and applies to a US-authorised device that is not currently an NHS treatment. The treatments that work today are still trauma-focused therapies, and they are available through the NHS. This is a promising addition, not a substitute. Sources: Nature Mental Health, Colvonen P et al., DOI 10.1038/s44220-026-00714-5, 23 September 2026, https://www.nature.com/natmentalhealth ; Medical Xpress, 'At-home electrical vestibular stimulation headset could ease PTSD symptoms', 23 September 2026, https://medicalxpress.com/news/2026-09-home-electrical-vestibular-headset-ease.html ; NHS, 'Post-traumatic stress disorder (PTSD)', https://www.nhs.uk/mental-health/conditions/post-traumatic-stress-disorder-ptsd/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.
Related articles
Six hours, not never: the ICU filter notice the MHRA issued today
The UK's medicines and devices regulator has issued a new safety notice to hospitals, and it is about timing. On 13 October 2026 the Medicines and Healthcare p…
Eight pages to a minister: what the data guardian says trust is worth
On 12 October 2026, the government published a letter about who should be trusted with NHS patient data. It was written by Dr Nicola Byrne, the National Data G…
Update: the tests came back, and it was not plague
This is a follow-up to a story we covered on 5 October, when nearly 200 people were being monitored after the death of a laboratory worker in Siberia. There has…